Clarity Pharmaceuticals (ASX:CU6) completed the dose escalation phase of its SECuRE trial, according to a Wednesday Australian bourse filing.
The safety review committee recommended that it proceed to the cohort expansion phase of the study at eight gigabecquerel dose level and increase the number of cycles from four to up to six.
The SECuRE trial assesses the safety and efficacy of the drug in the treatment of patients with metastatic castrate-resistant prostate cancer.
It said that across all cohorts of the dose escalation phase, 68% of the participants showed a reduction in prostate-specific antigen, despite 77% of the participants only receiving a single dose of copper-67-SAR-bisPSMA. It also showed a favorable safety profile across all cohorts.
The SECuRE trial protocol was amended to administer copper-67-SAR-bisPSMA to participants at earlier stages of the disease, in a pre-chemotherapy setting, incorporating an increase in the number of participants from 14 to 24, with a subset expected to receive a combination with enzalutamide.
The firm's shares rose 4% in recent trading on Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.